Journal article

Familial Hypercholesterolaemia in 2020: A Leading Tier 1 Genomic Application

Jing Pang, David R Sullivan, Tom Brett, Karam M Kostner, David L Hare, Gerald F Watts

Heart, Lung and Circulation | ELSEVIER SCIENCE INC | Published : 2020


Familial hypercholesterolaemia (FH) is caused by a major genetic defect in the low-density lipoprotein (LDL) clearance pathway. Characterised by LDL-cholesterol elevation from birth, FH confers a significant risk for premature coronary artery disease (CAD) if overlooked and untreated. With risk exposure beginning at birth, early detection and intervention is crucial for the prevention of CAD. Lowering LDL-cholesterol with lifestyle and statin therapy can reduce the risk of CAD. However, most individuals with FH will not reach guideline recommended LDL-cholesterol targets. FH has an estimated prevalence of approximately 1:250 in the community. Multiple strategies are required for screening, d..

View full abstract

University of Melbourne Researchers